ADGRE5

Adhesion G protein-coupled receptor E5 · P48960 · ADGRE5 on Sugi Atlas →

0 patent compounds predicted against ADGRE5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ADGRE5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation PHASE4COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules PHASE2UNKNOWN
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer PHASE1/PHASE2COMPLETED
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment PHASE1/PHASE2WITHDRAWN
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC PHASE2RECRUITING
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations PHASE1COMPLETED
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients EARLY_PHASE1COMPLETED
Platelet Activity in T2DM Using Flowcytometry nanUNKNOWN
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases nanUNKNOWN
Thrombin Regulated Platelet Activation nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients nanCOMPLETED
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues nanUNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers nanUNKNOWN
Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA nanCOMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ADGRE5 binder may also engage these)

ProteinNameSimilarity
Q8SQA4 1.000 Q8SQA4 →
Q9Z0M6 0.993 Q9Z0M6 →
Q8VEC3 0.991 Q8VEC3 →
Q58Y75 0.990 Q58Y75 →
Q59I63 0.988 Q59I63 →
Q9ESC1 0.988 Q9ESC1 →
D4A3T6 0.987 D4A3T6 →
ADGRF1 Adhesion G-protein coupled receptor F1 0.986 landscape →
Q923X1 0.986 Q923X1 →
O94910 0.984 O94910 →
Q9HBW9 0.984 Q9HBW9 →
Q00495 0.984 Q00495 →
A3QNZ8 0.983 A3QNZ8 →
Q80TR1 0.983 Q80TR1 →
Q5IXF8 0.983 Q5IXF8 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.983 landscape →
P22891 0.982 P22891 →
E9Q4J9 0.982 E9Q4J9 →
Q8JZZ7 0.982 Q8JZZ7 →
P79263 0.982 P79263 →
A3QP00 0.981 A3QP00 →
O35659 0.981 O35659 →
Q8IZF7 0.981 Q8IZF7 →
F7 Coagulation factor VII 0.981 landscape →
A3QP07 0.981 A3QP07 →
O95838 0.981 O95838 →
O97817 0.981 O97817 →
Q2F9P2 0.981 Q2F9P2 →
P31394 0.981 P31394 →
O88923 0.981 O88923 →